Press release
DelveInsight's 2023 Update on HDAC Inhibitor Pipeline Drugs: FDA Approvals, Clinical Trials, Mechanism of Action | Roche, Takeda, Italfarmaco, Sulfidris, MethylGene, EpiGen Pharmaceuticals, DAC Research, Karus Therapeutics, Xynomic Pharmaceuticals, Medivi
HDAC Inhibitor Pipeline
"HDAC Inhibitor Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the HDAC Inhibitor Market.
The HDAC Inhibitor Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Request for Sample Report here @ https://www.delveinsight.com/report-store/hdac-inhibitor-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr
Some of the key takeaways from the HDAC Inhibitor Pipeline Report:
• Companies across the globe are diligently working toward developing novel HDAC Inhibitor treatment therapies with a considerable amount of success over the years.
• HDAC Inhibitor companies working in the treatment market are Roche, Takeda, Italfarmaco, Sulfidris, MethylGene, EpiGen Pharmaceuticals, DAC Research, Karus Therapeutics, Xynomic Pharmaceuticals, Medivir, Mirati Therapeutics, Janssen Pharmaceuticals, and others, are developing therapies for the HDAC Inhibitor treatment
• Emerging HDAC Inhibitor therapies such as - Givinostat, Research programme: histone deacetylase inhibitors, ACS 33, MG 4915, AP CANC04, DAC 0060, KAR 2581, Abexinostat, Remetinostat, Mocetinostat, Quisinostat, and others are expected to have a significant impact on the HDAC Inhibitor market in the coming years.
• In March 2021, AlloVir initiated a Phase III study to evaluate ALVR105 (Viralym-M); an allogeneic, off the-shelf multi-virus specific T cell therapy that targets six viral pathogens: BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6 and JC virus
• In October 2021, the US Food and drug administration (FDA) granted Orphan Drug Designation (ODD) to posoleucel (ViralymM, ALVR105) for the treatment of virus-associated hemorrhagic cystitis (HC). This Orphan Drug Designation acknowledges the urgent need for new treatment options for patients who have undergone hematopoietic stem cell transplantation and are at risk for developing viral infections and hemorrhagic cystitis
HDAC Inhibitor Overview
HDAC inhibitors are a class of pharmaceutical compounds that target enzymes called histone deacetylases (HDACs). HDACs play a crucial role in gene expression regulation by removing acetyl groups from histone proteins, which are involved in packaging DNA and influencing its accessibility to transcription factors and other proteins.
By inhibiting HDAC activity, HDAC inhibitors alter the acetylation status of histones, leading to changes in gene expression patterns. This can result in a wide range of biological effects, including anti-cancer, anti-inflammatory, and neuroprotective activities. HDAC inhibitors have gained significant attention as potential therapeutic agents for various diseases, particularly cancer.
Get a Free Sample PDF Report to know more about HDAC Inhibitor Pipeline Therapeutic Assessment @ https://www.delveinsight.com/sample-request/hdac-inhibitor-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr
Route of Administration
HDAC Inhibitor pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravaginal
• Oral
• Parenteral
• Subcutaneous
• Topical
Molecule Type
Products have been categorized under various Molecule types, such as
• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Product Type
HDAC Inhibitor Pipeline Therapeutics Assessment
• HDAC Inhibitor Assessment by Product Type
• HDAC Inhibitor By Stage and Product Type
• HDAC Inhibitor Assessment by Route of Administration
• HDAC Inhibitor By Stage and Route of Administration
• HDAC Inhibitor Assessment by Molecule Type
• HDAC Inhibitor by Stage and Molecule Type
DelveInsight's HDAC Inhibitor Report covers around 4+ products under different phases of clinical development like-
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Further HDAC Inhibitor product details are provided in the report. Download the HDAC Inhibitor pipeline report to learn more about the emerging HDAC Inhibitor therapies @ https://www.delveinsight.com/report-store/hdac-inhibitor-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr
HDAC Inhibitor Pipeline Analysis:
The HDAC Inhibitor pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of HDAC Inhibitor with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for HDAC Inhibitor Treatment.
• HDAC Inhibitor key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• HDAC Inhibitor Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the HDAC Inhibitor market.
Download Sample PDF Report to know more about HDAC Inhibitor drugs and therapies @ https://www.delveinsight.com/sample-request/hdac-inhibitor-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr
HDAC Inhibitor Pipeline Market Drivers
One of the major HDAC Inhibitor market drivers for HDAC inhibitors is their potential in cancer treatment. These inhibitors have demonstrated efficacy in preclinical and clinical studies, showing the ability to inhibit tumor growth, induce cell death, and sensitize cancer cells to other therapies. The demand for novel cancer treatments drives the interest in HDAC inhibitors.
HDAC Inhibitor Pipeline Market Barriers
However Safety and Tolerability Concerns, Limited Clinical Success, Drug Specificity and Selectivity and other factors are creating obstacles in the HDAC Inhibitor Market growth.
Scope of HDAC Inhibitor Pipeline Drug Insight
• Coverage: Global
• Key HDAC Inhibitor Companies: Roche, Takeda, Italfarmaco, Sulfidris, MethylGene, EpiGen Pharmaceuticals, DAC Research, Karus Therapeutics, Xynomic Pharmaceuticals, Medivir, Mirati Therapeutics, Janssen Pharmaceuticals, and others
• Key HDAC Inhibitor Therapies: Givinostat, Research programme: histone deacetylase inhibitors, ACS 33, MG 4915, AP CANC04, DAC 0060, KAR 2581, Abexinostat, Remetinostat, Mocetinostat, Quisinostat, and others.
• HDAC Inhibitor Therapeutic Assessment: HDAC Inhibitor current marketed and HDAC Inhibitor emerging therapies
• HDAC Inhibitor Market Dynamics: HDAC Inhibitor market drivers and HDAC Inhibitor market barriers
Request for Sample PDF Report for HDAC Inhibitor Pipeline Assessment and clinical trials @ https://www.delveinsight.com/sample-request/hdac-inhibitor-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr
Table of Contents
1. HDAC Inhibitor Report Introduction
2. HDAC Inhibitor Executive Summary
3. HDAC Inhibitor Overview
4. HDAC Inhibitor- Analytical Perspective In-depth Commercial Assessment
5. HDAC Inhibitor Pipeline Therapeutics
6. HDAC Inhibitor Late Stage Products (Phase II/III)
7. HDAC Inhibitor Mid Stage Products (Phase II)
8. HDAC Inhibitor Early Stage Products (Phase I)
9. HDAC Inhibitor Preclinical Stage Products
10. HDAC Inhibitor Therapeutics Assessment
11. HDAC Inhibitor Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. HDAC Inhibitor Key Companies
14. HDAC Inhibitor Key Products
15. HDAC Inhibitor Unmet Needs
16 . HDAC Inhibitor Market Drivers and Barriers
17. HDAC Inhibitor Future Perspectives and Conclusion
18. HDAC Inhibitor Analyst Views
19. Appendix
20. About DelveInsight
Trending Reports:
• Abetalipoproteinemia Market: https://www.delveinsight.com/report-store/abetalipoproteinemia-market
• Polycythemia Market: https://www.delveinsight.com/report-store/polycythemia-vera-market
• Ambulatory Arrhythmia Monitoring Devices Market: https://www.delveinsight.com/report-store/ambulatory-arrhythmia-monitoring-devices-market
• Choroidal Neovascularization Market: https://www.delveinsight.com/report-store/choroidal-neovascularization-market
• Pruritus Market: https://www.delveinsight.com/report-store/pruritus-market
• Cardiopulmonary Bypass Equipment Market: https://www.delveinsight.com/report-store/cardiopulmonary-bypass-equipment-market
• Chemotherapy Induced Anemia Market: https://www.delveinsight.com/report-store/chemotherapy-induced-anemia-market
• Chronic Bronchitis Market: https://www.delveinsight.com/report-store/chronic-obstructive-pulmonary-disease-copd-market
• Clbp Market: https://www.delveinsight.com/report-store/chronic-lower-back-pain-clbp-market
• Hearing Implants Market: https://www.delveinsight.com/report-store/hearing-implants-market
• Neurovascular Devices Market: https://www.delveinsight.com/report-store/neurovascular-devices-interventional-neurology-market
• Pemphigus Vulgaris Market: https://www.delveinsight.com/infographics/pemphigus-vulgaris-market
• Polycythemia Vera Market: https://www.delveinsight.com/report-store/polycythemia-vera-market
• Advanced Renal Cell Carcinoma Market: https://www.delveinsight.com/report-store/advanced-renal-cell-carcinoma-rcc-market
• Airway Stent Market Market: https://www.delveinsight.com/report-store/airway-stent-market
• Allergic Conjunctivitis Market: https://www.delveinsight.com/report-store/allergic-conjunctivitis-market
• Alopecia Areata Market: https://www.delveinsight.com/report-store/alopecia-areata-market
• Alport Syndrome Market: https://www.delveinsight.com/report-store/alport-syndrome-market
• Angioedema Market: https://www.delveinsight.com/report-store/angioedema-market
• Bladder Pain Syndrome Market: https://www.delveinsight.com/report-store/interstitial-cystitis-market
• Bone Densitometers Market: https://www.delveinsight.com/report-store/bone-densitometers-market
• Brain Aneurysm Stents Market: https://www.delveinsight.com/report-store/brain-aneurysm-stents-market
• Calciphylaxis Market: https://www.delveinsight.com/report-store/calciphylaxis-market
• Chronic Inflammatory Demyelinating Polyneuropathy Market: https://www.delveinsight.com/report-store/chronic-inflammatory-demyelinating-polyneuropathy-cidp-market
• Chronic Inflammtory Demyelinating Polyneuropathy Market: https://www.delveinsight.com/report-store/chronic-inflammatory-demyelinating-polyneuropathy-cidp-market
• Chronic Myelogenous Leukemia Market: https://www.delveinsight.com/report-store/chronic-myeloid-leukemia-market
• Cutaneous T-cell Lymphoma Market: https://www.delveinsight.com/report-store/cutaneous-t-cell-lymphoma-ctcl-market
• Defibrillators Market: https://www.delveinsight.com/report-store/defibrillator-market
• Dermal Erythema Market: https://www.delveinsight.com/report-store/dermal-erythema-market
• Eczema Market: https://www.delveinsight.com/report-store/atopic-dermatitis-market
Contact Info:
Ankit Nigam
Assistant Manager (Marketing & Branding)
Email: info@delveinsight.com
428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release DelveInsight's 2023 Update on HDAC Inhibitor Pipeline Drugs: FDA Approvals, Clinical Trials, Mechanism of Action | Roche, Takeda, Italfarmaco, Sulfidris, MethylGene, EpiGen Pharmaceuticals, DAC Research, Karus Therapeutics, Xynomic Pharmaceuticals, Medivi here
News-ID: 3266086 • Views: …
More Releases from DelveInsight Business Research
Immune Checkpoint Inhibitors Market Outlook 2034: Competitive Landscape, Pipelin …
DelveInsight's latest report, "Immune Checkpoint Inhibitors Market Forecast (2020-2034)", provides an in-depth analysis of one of the most transformative areas in oncology. According to DelveInsight estimates, the Immune Checkpoint Inhibitors (ICI) market is expected to grow at a decent CAGR throughout the forecast period, driven by the rising global burden of cancer, advances in immuno-oncology, increasing healthcare expenditures, and the anticipated approval of novel ICIs across the 7MM [the United…
HPK1 Inhibitors Market Outlook 2034: Competitive Landscape, Pipeline Advancement …
(Albany, USA, September 2025) - DelveInsight has released its latest report, "HPK1 Inhibitor Competitive Landscape And Market Forecast - 2034," delivering an in-depth analysis of the rapidly evolving HPK1 inhibitor market. The report offers a comprehensive overview of the epidemiology, drug uptake, treatment landscape, competitive intelligence, and market dynamics shaping the outlook of HPK1 inhibitors across the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.
To know…
Focal Adhesion Kinase (FAK) Inhibitors Market Outlook 2034: Scientific Advances, …
(Albany, USA, September 2025) - Focal Adhesion Kinase (FAK), also known as PTK2, has emerged as one of the most promising molecular targets in oncology research and therapy development. Encoded by the PTK2 gene, FAK is a non-receptor tyrosine kinase critically involved in signal transduction mediated by growth factor receptors and integrins. Increasing evidence shows that overexpression of FAK is directly associated with tumor progression, therapy resistance, and poor clinical…
Thyroid Eye Disease Market Set for Robust Expansion Through 2034, DelveInsight R …
DelveInsight's "Thyroid Eye Disease Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Thyroid Eye Disease, historical and forecasted epidemiology as well as the Thyroid Eye Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Thyroid Eye Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Thyroid Eye Disease…
More Releases for DAC
CJC 1295 DAC for Bodybuilding - A Smart Lifter's Guide
If you care about progress more than hype, you already know that long-term physique changes come from training quality, calorie control, and sleep. Where many athletes still struggle is in recovery capacity and in keeping hard sessions productive when fatigue piles up. That's why interest keeps circling back to growth-hormone (GH) support-not by injecting GH itself, but by nudging your own system to release more. Enter CJC-1295 with DAC: a…
Direct Air Capture (DAC or DACCS) Market Key Players, Share and Forecast Outlook
"The global Direct Air Capture (DAC) market is projected to reach approximately $1.4 billion in 2024, with a robust growth trajectory anticipated throughout the forecast period of 2025 to 2034. Experts suggest the market could grow to around $6.3 billion by 2034, reflecting a Compound Annual Growth Rate (CAGR) of about 17.1%. "
Exactitude Consultancy., Ltd. released a research report titled "Direct Air Capture (DAC or DACCS) Market". This report covers…
New Generation DAC Cables: Enhancing Data Center Connectivity Efficiency
As the scale of data centers continues to expand and performance demands increase, the new generation of DAC cables is becoming a crucial solution for optimizing data center connectivity efficiency. By employing advanced technology, DAC cables not only improve transmission rates but also significantly reduce energy consumption and costs, making them the preferred choice for data center managers. This article delves into the application of new generation DAC cables in…
NAD Electronics Introduces the C 379 HybridDigital DAC Amplifier
The new addition to the Classic Series combines innovation and value to deliver refined performance and sound quality.
MAY 2, 2024 - MUNICH, GERMANY - NAD Electronics, a leading manufacturer in high-performance audio, today announces the launch of its new Classic Series amplifier, the C 379 HybridDigital DAC Amplifier at the HIGH END Munich International Audio Show. The C 379 builds on NAD's commitment to innovation and value-driven performance with a…
Global DAC System Market Research Report 2023-2029
DAC System refers to a process that captures carbon dioxide (CO2) directly from the atmosphere. It is a technology aimed at reducing greenhouse gas emissions and mitigating climate change. Unlike other carbon capture methods that capture CO2 from industrial emissions or power plant flue gases, DAC systems capture CO2 directly from ambient air, regardless of its source.
Global DAC System Market: Driven factors and Restrictions factors
The research report encompasses a comprehensive…
NEW: Temperature sensitive laboratory mixing with Hauschild SpeedMixer® SMART D …
Hauschild presents a new highly sophisticated series of intelligent DAC (Dual Asymmetric Centrifugal) laboratory mixers: the Hauschild SpeedMixer® SMART DAC Series with real-time jar's temperature control, cooling, robotic, vacuum and many other new unique features. At the same time, the company asks its customers in Europe, especially in the Benelux region and the U.S. to carefully check their equipment with the name "SpeedMixer" - without the addition of Hauschild. The…
